Emi1 Activators
Emi1 (Early Mitotic Inhibitor 1) plays a pivotal role in the regulation of the cell cycle, particularly in the transition from the G1 to the S phase and the subsequent progression through mitosis. It functions by inhibiting the Anaphase-Promoting Complex/Cyclosome (APC/C), a critical E3 ubiquitin ligase, thus preventing the premature degradation of cell cycle regulators such as cyclins and securing a controlled progression through the cell cycle phases. This action is crucial for maintaining genomic stability and ensuring the accurate duplication and segregation of chromosomes. By inhibiting APC/C, Emi1 allows for the accumulation of mitotic cyclins and the proper initiation and completion of mitosis, playing a vital role in cell cycle control and the prevention of unscheduled cell division, which could lead to genomic instability or oncogenesis.
The general mechanism of Emi1 activation, particularly through indirect means, involves the modulation of cellular pathways that influence the stability and activity of cell cycle regulators. Chemicals that increase intracellular cAMP levels, either through direct activation of adenylate cyclase or inhibition of phosphodiesterases, lead to the activation of PKA and subsequent downstream effects that can indirectly support the stabilization and activity of Emi1. This elevation in cAMP and activation of PKA create a cellular environment that discourages premature APC/C activation, thus indirectly supporting the function of Emi1 in maintaining cell cycle integrity. Through these mechanisms, the selected chemicals contribute to the regulation of the cell cycle by ensuring that Emi1 can effectively perform its role as an inhibitor of APC/C, thereby promoting genomic stability and proper cell cycle progression without direct interaction with Emi1 itself. This highlights the importance of understanding the interconnectedness of cellular signaling pathways and the impact of small molecules on these networks in the regulation of critical cellular functions.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, increasing cAMP levels, which in turn, can enhance the proteasomal degradation of cyclin-dependent kinase inhibitors. This indirectly leads to the activation of Emi1 by promoting its stabilizing environment, essential for cell cycle progression. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX inhibits phosphodiesterases, preventing cAMP degradation, thus potentiating cAMP-dependent pathways. Elevated cAMP indirectly activates Emi1 by reinforcing pathways that stabilize the cell cycle, thereby supporting Emi1's role in inhibiting premature APC/C activation. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Br-cAMP, a cAMP analog, activates PKA (Protein Kinase A), leading to downstream effects that can enhance Emi1 activity. This activation supports the stabilization of the cell cycle phase specific for Emi1's action, by preventing the premature ubiquitination and degradation of cell cycle regulators. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram inhibits PDE4, leading to increased cAMP in cells, which indirectly activates Emi1 through the cAMP/PKA pathway. This elevation in cAMP levels can enhance the cell cycle regulatory environment favorable to Emi1's function, promoting proper cell cycle progression without premature APC/C activation. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Cilostamide inhibits PDE3, resulting in increased cAMP levels, indirectly supporting Emi1 activation by promoting a cellular environment that favors the stabilization of cell cycle regulators, essential for Emi1 to effectively inhibit APC/C and maintain cell cycle integrity. | ||||||
Milrinone | 78415-72-2 | sc-201193 sc-201193A | 10 mg 50 mg | $165.00 $697.00 | 7 | |
Milrinone, a PDE3 inhibitor, increases intracellular cAMP, indirectly facilitating Emi1 activation by enhancing the cellular context for the preservation of cell cycle progression, thereby supporting Emi1's role in delaying APC/C activation and ensuring orderly cell cycle transition. | ||||||
Anagrelide | 68475-42-3 | sc-491875 | 25 mg | $150.00 | ||
Anagrelide, another PDE3 inhibitor, elevates cAMP levels, thus indirectly activating Emi1 by creating conditions conducive to the maintenance of cell cycle phase stability, crucial for Emi1's function in preventing untimely APC/C activation and sustaining cell division. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Zaprinast, a PDE5 inhibitor, raises cAMP levels, indirectly activating Emi1 by contributing to a cellular milieu that supports the regulation of cell cycle transitions, thereby aiding Emi1 in its role to inhibit premature activation of APC/C, facilitating orderly progression through the cell cycle. | ||||||
Vinpocetine | 42971-09-5 | sc-201204 sc-201204A sc-201204B | 20 mg 100 mg 15 g | $55.00 $214.00 $2400.00 | 4 | |
Vinpocetine, a PDE1 inhibitor, enhances cAMP levels in cells, indirectly activating Emi1 by promoting a cellular environment that favors the regulation of cell cycle checkpoints, thus aiding Emi1 in its crucial role in preventing the premature activation of APC/C. | ||||||
Pentoxifylline | 6493-05-6 | sc-203184 | 1 g | $20.00 | 3 | |
Pentoxifylline, by inhibiting phosphodiesterase, increases cAMP levels, thereby indirectly activating Emi1. This activation facilitates a cellular environment that prevents the early initiation of APC/C, supporting Emi1's essential role in cell cycle control and stability. | ||||||